Search

MicroRNA-139-5p (miR-139-5p) plays a crucial role in cancer’s onset and progression and is considered a tumor suppressor gene. However, the biological functions and mechanism of miR-139-5p in the tumorigenicity in Non-small cell lung cancer (NSCLC) has received insufficient investigation. We investigated the miR-139-5p expression in lung cancer tissues and the adjacent normal lung tissues, in 54 NSCLC patients. Additionally, the miR-139-5p target gene was predicted by bioinformatics analysis and then confirmed by a dual-luciferase reporter assay. The biological functions of miR-139-5p and the target gene have been investigated, in both in vitro and in vivo studies. Finally, the anti-tumor effects of miR-139-5p were corroborated by tumor formation assay in nude mice and progression-free survival analysis in another 144 NSCLC patients. MiR-139-5p was down-regulated, and inversely correlated with DNA topoisomerase II alpha (TOP2A), in both NSCLC tissues and cells. In vitro, miR-139-5p overexpression suppressed proliferation, migration, and invasion by down-regulating TOP2A in normal human bronchial epithelioid cells and NSCLC cell lines. It also induced apoptosis in NSCLC cell lines. In vivo, miR-139-5p up-regulation and the TOP2A mRNA down-regulation were significantly correlated, with longer progression-free survival times in 144 NSCLC patients. Moreover, miR-139-5p overexpression mitigated the xenograft tumor formation. MiR-139-5p inhibited growth and metastasis in NSCLC cell lines via direct TOP2A targeting. Low miR-139-5p expression showed a significant correlation with poor prognosis in NSCLC patients. These results highlight the effect of miR-139-5p on NSCLC, suggesting that miR-139-5p is a promising biomarker for NSCLC prognosis and an exceptional candidate for further therapeutic exploration.

Background Increasing evidences have showed that neuroimaging markers of SVD can predict the short-term outcome of acute ischemic stroke (AIS). It is unclear that whether neuroimaging markers of SVD are also associated with short-term outcomes of minor cerebrovascular events. In the present study, we investigate neuroimaging markers of SVD in order to explore their roles in prediction of short-term outcome in patients with minor cerebrovascular events. Methods Consecutive first-ever stroke patients (n = 546) from the Affiliated Jiangning Hospital of Nanjing Medical University were enrolled. A total of 388 patients were enrolled according to minor cerebrovascular events definition (National Institutes of Health Stroke Scale Score ≤ 3) and exclusion criteria. MRI scans were performed within 7 days of stroke onset, and then neuroimaging markers of SVD including WMH, lacunes, cerebral microbleeds (CMB), and perivascular spaces (PVS), SVD burden scores were assessed. We completed baseline characteristics and evaluated the relationships of short-term outcomes to SVD neuroimaging markers and SVD scores. The 90-day modified Rankin Scale (mRS) was thought as primary outcome and was dichotomized as good functional outcome (mRS 0–1) and poor outcome (mRS 2–6). Secondary outcomes were stroke progression and stroke recurrence. Results Higher age, National Institutes of Health Stroke Scale (NIHSS) upon admission, lipoprotein-associated phospholipase A2 (LP-PLA2) and lacunes, Fazekas score were correlated with poor functional outcome (P P = 0.036) was found to be associated with poor outcome at 90 days. Higher Fazekas and SVD scores were not associated with stroke progression or stroke recurrence. Conclusion WMH can predict the poor functional outcome of minor cerebrovascular events. Adding other neuroimaging markers of SVD and total SVD burden score, however, does not improve the prediction, which indicated WMH can as neuroimaging markers for guiding the treatment of minor cerebrovascular events.